Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study

Diabetologia

Volumn 48, Issue 2, 2005, Pages 215-221

  Mackin, P ^a   Watkinson, H M ^a   Young, A H ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Antipsychotic drugs; Atypical antipsychotic drugs; Diabetes; Diagnosis; Dyslipidaemia; Glucose homeostasis; Metabolic syndrome; Obesity

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLESTEROL; CLOZAPINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZUCLOPENTHIXOL DECANOATE;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; BODY MASS; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; MOOD DISORDER; OBESITY; PANCREAS ISLET CELL; PREVALENCE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; ENGLAND; ETHNIC GROUPS; FEMALE; GLUCOSE; GLUCOSE INTOLERANCE; HOMEOSTASIS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREVALENCE; PSYCHOTIC DISORDERS;

EID: 17444405568     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1641-y     Document Type: Article

References (30)

1. Maudsley H (1979) The pathology of mind. 3rd edn., Macmillan, London
2. Charatan FBE, Bartlett NG (1955) The effect of chlorpromazine on glucose tolerance. J Ment Sci 191:351-353
3. Freeman H (1946) Resistance to insulin in mentally disturbed soldiers. Arch Neurol Psych 56:74-77
4. Kane J, Honigfeld G, Singer J et al (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
5. Yatham LN (2003) Efficacy of atypical antipsychotics in mood disorders. J Clin Psychopharmacol 23(3 Suppl 1):S9-S14
6. Koller EA, Doraiswamy PM (2002) Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841-852
7. Lean ME, Pajonk FG (2003) Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 26:1597-1605
8. Croarkin PE, Jacobs KM, Bain BK (2000) Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 41:369-370
9. Lindenmayer JP, Czobor P, Volavka J et al. (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160:290-296
10. Hedenmalm K, Hagg S, Stahl M et al (2002) Glucose intolerance with atypical antipsychotics. Drug Safety 25:1107-1116
11. Mokdad AH, Ford ES, Bowman BA et al (2001) Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 289:76-79
12. Shiloah E, Witz S, Abramovitch Y et al (2003) Effect of acute psychotic stress in nondiabetic subjects on beta-cell function and insulin sensitivity. Diabetes Care 26:1462-1467
13. Bushe C, Holt R (2004) Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl 47:S67-S71
14. Consensus development conference on antipsychotic drugs and obesity and diabetes (2004) Diabetes Care 27:596-601
15. Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191-2192
16. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057
17. World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. WHO Bulletin 1-59
18. Fulton-Kehoe D, Hamman RF, Baxter J et al. (2001) A case-control study of physical activity and non-insulin dependent diabetes mellitus (NIDDM). The San Luis Valley Diabetes Study. Ann Epidemiol 11:320-327
19. Martinsen EW, Strand J, Paulsson G et al. (1989) Physical fitness level in patients with anxiety and depressive disorders. Int J Sports Med 10:58-61
20. Hill JO, Wyatt HR, Reed GW et al. (2003) Obesity and the environment: where do we go from here? Science 299:853-855
21. Baptista T, Kin NM, Beaulieu S et al. (2002) Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35:205-219
22. Thakore JH (2004) Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 47:S76-S79
23. Fagiolini A, Frank E, Houck PR et al. (2002) Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 63:528-533
24. Lucksted A, McGuire C, Postrado L et al (2004) Specifying cigarette smoking and quitting among people with serious mental illness. Am J Addict 13:128-138
25. Taylor D, Young C, Esop R et al. (2004) Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 185:152-156
26. Haffner S, Cassells HB (2003) Metabolic syndrome - a new risk factor of coronary heart disease? Diabetes Obes Metab 5:359-370
27. Allison DB, Mentore JL, Heo M et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696
28. Brecher M (2000) The long-term effect of quetiapine (seroquel) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 4:287-291
29. Taylor DM, McAskill R (2000) Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 101:416-432
30. Melkersson K, Dahl ML (2004) Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64:701-723